trending Market Intelligence /marketintelligence/en/news-insights/trending/WuRSy7GJv36tHjdDRuNmQg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Abcam completes €120M acquisition of businesses from Expedeon

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Abcam completes €120M acquisition of businesses from Expedeon

Abcam PLC has completed its acquisition of the proteomics and immunology businesses of Expedeon AG.

Abcam CEO Alan Hirzel said acquiring the German biotechnology company adds its product and technology portfolio to Abcam's antibody research and tools.

In November, Cambridge, England-based Abcam announced its intent to acquire Expedeon's three proteomics and immunology businesses — Expedeon Ltd., Innova Biosciences Ltd. and TGR BioSciences— for €120 million in cash.

In January 2019, Abcam bought antibodies developer Calico Biolabs Inc. to expand its production capabilities.